A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer

被引：0
|
作者：
Collins, Jenna [1 ]
Nordstrom, Beth [1 ]
Kwong, Jackie [2 ]
Murphy, Brian [1 ]
Pavilack, Melissa [3 ]
机构：
[1] Evidera, Waltham, MA USA
[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS7-82
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world survival of Danish patients with HER2-positive metastatic breast cancer
    Artzi, Daniel
    Berg, Tobias
    Celik, Alan
    Kumler, Iben
    Kenholm, Julia
    Al-Rawi, Sami
    Jensen, Maj-Britt
    Andersson, Michael
    Knoop, Ann
    [J]. ACTA ONCOLOGICA, 2023, 62 (06) : 601 - 607
  • [2] Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
    Zhang, Qiongwen
    He, Ping
    Tian, Tinglun
    Yan, Xi
    Huang, Juan
    Zhang, Zhang
    Zheng, Hong
    Zhong, Xiaorong
    Luo, Ting
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] A real-world evidence study of treatment patterns in patients with HER2-positive metastatic breast cancer who have received at least 2-lines of therapy
    Varghese, Della
    Cruz, Giovanna I.
    Johanson, Colden
    Toland, Liz
    Miranda, Miguel
    Faherty, Eleanor C.
    Harland, David
    Kaplan, Henry G.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [4] Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
    Gui, Xinyu
    Li, Huiping
    Yan, Ying
    Zhang, Ruyan
    [J]. ONCOLOGY LETTERS, 2020, 20 (06)
  • [5] A real-world study on prevalence of and outcomes related to brain metastases among patients with HER2-positive metastatic breast cancer (mBC)
    Collins, J.
    Varghese, D.
    Miranda, M.
    Nordstrom, B.
    Murphy, B.
    Harland, D.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S213 - S213
  • [6] Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
    Kaufman, Peter A.
    Neuberger, Edward
    Schwartz, Naomi R. M.
    Wang, Shu
    Liu, Yutong
    Hsu, Ling-, I
    Bartley, Karen
    Blahna, Matthew T.
    Pittner, Brian T.
    Wong, Gabriel
    Anders, Carey
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer
    Vidal, G. A.
    Debusk, K.
    Gautam, S.
    Vlahiotis, A.
    Fisher, M.
    Pulgar, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S78 - S78
  • [8] Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada
    Gambaro, Karen
    Groleau, Melanie
    Mcnamara, Suzan
    Awan, Arif
    Salem, Maged
    Abdelsalam, Mahmoud
    St-Hilaire, Eve
    Vincent, Francois
    Carrier, Julie
    Mackay, Helen
    Provencher, Louise
    Boudreau, Dominique
    Hamilou, Zineb
    Saad, Fred
    Ferrario, Cristiano
    Batist, Gerald
    Marques, Maud
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2023, 26 : 12078
  • [9] A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
    Jin, N.
    Yin, Y.
    Li, W.
    Huang, X.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [10] Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
    Luo, T.
    Zhang, Q.
    He, P.
    Zhong, X.
    Yan, X.
    Tian, T.
    Huang, J.
    Zhang, Z.
    Zheng, H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
12345